Navigation Links
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
Date:9/2/2008

SAN FRANCISCO, Sept. 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Wednesday, September 3, to discuss partnering plans for Dimebon.

Teleconference/Webcast Details

To participate in the live call on Wednesday, September 3, at 8:30 a.m. Eastern Time by telephone, please dial 877-681-3375 from the U.S. or +1-719-325-4933 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medivation Announces Participation in Upcoming Conferences
2. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
3. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
4. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
6. Medivation Announces Senior Management Promotions
7. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
8. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
10. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
11. Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4First-in-class treatment for acute leukemia 2First-in-class treatment for acute leukemia 3Self-destructing bacteria improve renewable biofuel production 2Self-destructing bacteria improve renewable biofuel production 3BioConference Live Call for Abstracts 47912 1BioConference Live Call for Abstracts 47912 2BioConference Live Call for Abstracts 47912 3BioConference Live Call for Abstracts 47912 4Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 1Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 2Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 3Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 4Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 5Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 6Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 7Girls and Math 3A Blame the Culture Not Ability 47904 1Girls and Math 3A Blame the Culture Not Ability 47904 2